Actinium Pharmaceuticals Inc (ATNM) FinancialsATNMActinium Pharmaceuticals Inc

Evaluating the bottom line, Actinium Pharmaceuticals Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 78.76%, while the net margin is 79.72%. These profitability ratios, combined with a Return on Equity (ROE) of 45.86%, provide a clear picture of how effectively ATNM converts its operational activities into shareholder value.

In the context of the broader market, ATNM competes directly with industry leaders such as BMEA and FRMM. With a market capitalization of $44.64M, it holds a leading position in the sector. When comparing efficiency, ATNM's gross margin of 100.00% stands against BMEA's N/A and FRMM's 29.16%. Such benchmarking helps identify whether Actinium Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Actinium Pharmaceuticals is showing promising financial performance with a projected revenue of $35 million in Q2 2026 and a net income of $27.9 million for the same quarter, indicating a turnaround from previous losses.